World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
111
Citations
53889
World Ranking
5276
National Ranking
2849

Overview

Gary K. Schwartz is affiliated with the Memorial Sloan Kettering Cancer Center in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics, and Molecular Biology, with a notable focus on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Cancer Research, and Hematology as subfields.

The scientist's work covers several important topics within cancer research and treatment, including:

  • Sarcoma Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • CAR-T cell therapy research
  • Protein Degradation and Inhibitors
  • Ocular Oncology and Treatments
  • Multiple Myeloma Research and Treatments
  • Immunotherapy and Immune Responses

Some recent papers featuring Gary K. Schwartz include:

  • Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium (2021) in Annals of Oncology
  • Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) (2020) in Clinical Trials
  • The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design (2020) in JNCI Journal of the National Cancer Institute
  • Dissecting the treatment-naive ecosystem of human melanoma brain metastasis (2022) in Cell
  • Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial (2024) in The Lancet

Gary K. Schwartz frequently collaborates with several researchers, including:

  • Matthew Ingham
  • Richard D. Carvajal
  • Steven Attia
  • Suzanne George
  • Brian Andrew Van Tine

The leading venues for their publications are:

  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Cancer Research
  • Cureus
  • Physician leadership journal

In addition to journal articles, Gary K. Schwartz has contributed to book publications. One known work is Rembrandt Seen Through Jewish Eyes, published in 2023 by Amsterdam University Press.

Best Publications

  • Guidelines for the use and interpretation of assays for monitoring autophagy

    Daniel J. Klionsky;Fabio C. Abdalla;Hagai Abeliovich;Robert T. Abraham

  • Tumour exosome integrins determine organotropic metastasis

    Ayuko Hoshino;Bruno Costa-Silva;Tang-Long Shen;Goncalo Rodrigues

  • Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry

    Ki Young Chung;Jinru Shia;Nancy E. Kemeny;Manish Shah

  • KIT as a therapeutic target in metastatic melanoma

    Richard D. Carvajal;Cristina R. Antonescu;Jedd D. Wolchok;Paul B. Chapman

  • Targeting the Cell Cycle: A New Approach to Cancer Therapy

    Gary K. Schwartz;Manish A. Shah

  • Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

    Jyoti D. Patel;Lada Krilov;Sylvia Adams;Carol Aghajanian

  • Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.

    Jordi Barretina;Barry S Taylor;Barry S Taylor;Shantanu Banerji;Shantanu Banerji;Alexis H Ramos;Alexis H Ramos

  • First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

    Josep Tabernero;Geoffrey I. Shapiro;Patricia M. LoRusso;Andres Cervantes

  • Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas

    Robert G. Maki;David R. D'Adamo;Mary L. Keohan;Michael Saulle

  • Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

    William D Tap;William D Tap;Robin L Jones;Robin L Jones;Brian A Van Tine;Bartosz Chmielowski

  • Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.

    Sandra P D'Angelo;Sandra P D'Angelo;Michelle R Mahoney;Brian A Van Tine;James Atkins

  • Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

    Manish A. Shah;Ramesh K. Ramanathan;David H. Ilson;Alissa Levnor

  • Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.

    Manish A. Shah;Gary K. Schwartz

  • Replacement of Fhit in cancer cells suppresses tumorigenicity

    Zurab Siprashvili;Gabriella Sozzi;Larry D. Barnes;Peter McCue

  • Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting lymphocyte count after 2 doses correlates with survival

    Geoffrey Y. Ku;Jianda Yuan;David B. Page;Sebastian E. A. Schroeder

  • AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.

    Sonya D Zabludoff;Chun Deng;Michael R Grondine;Adam M Sheehy

  • Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma

    Mark A. Dickson;William D. Tap;Mary Louise Keohan;Sandra P. D'Angelo

  • Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma: A Randomized Clinical Trial

    Richard D. Carvajal;Jeffrey A. Sosman;Jorge Fernando Quevedo;Mohammed M. Milhem

  • Sorafenib for Advanced and Refractory Desmoid Tumors.

    Mrinal M. Gounder;Michelle R. Mahoney;Brian A. Van Tine;Vinod Ravi

  • Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

    Keith T. Flaherty;Patricia M. LoRusso;Angela DeMichele;Vandana G. Abramson

Frequent Co-Authors

Richard D. Carvajal
Richard D. Carvajal Columbia University
David P. Kelsen
David P. Kelsen Memorial Sloan Kettering Cancer Center
Samuel Singer
Samuel Singer Memorial Sloan Kettering Cancer Center
Robert G. Maki
Robert G. Maki University of Pennsylvania
Manish A. Shah
Manish A. Shah Cornell University
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Eileen M. O’Reilly
Eileen M. O’Reilly Memorial Sloan Kettering Cancer Center
Leonard Saltz
Leonard Saltz Memorial Sloan Kettering Cancer Center
Paul B. Chapman
Paul B. Chapman Memorial Sloan Kettering Cancer Center
Mithat Gonen
Mithat Gonen Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in healthcare careers beyond medical school, several flexible online degree options are available. Many nursing professionals look for programs that allow them to advance their education while balancing work and personal commitments. For instance, rn to bsn online no clinicals programs enable registered nurses to earn a bachelor’s degree without the requirement of in-person clinical hours, making it easier to fit studies around a busy schedule.

Those aiming for leadership roles might consider online dnp programs, which allow students to attain the highest level of nursing practice. Similarly, there are easy dnp programs offering streamlined coursework for qualified professionals seeking career progression.

If you’re just starting in healthcare, there are also 9 month lpn program options that provide a fast track into practical nursing. Exploring these related online degrees and pathways can help you choose an educational journey that fits your goals and lifestyle.

Best Scientists Citing Gary K. Schwartz

Trending Scientists

Recently Published Articles